Crossmark Global Holdings Inc. bought a new position in shares of Glaukos Co. (NYSE:GKOS – Get Rating) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 4,230 shares of the medical instruments supplier’s stock, valued at approximately $225,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Glaukos by 1.9% in the 1st quarter. Vanguard Group Inc. now owns 5,215,765 shares of the medical instruments supplier’s stock valued at $301,575,000 after purchasing an additional 99,170 shares during the period. State Street Corp raised its position in Glaukos by 1.0% during the second quarter. State Street Corp now owns 1,698,257 shares of the medical instruments supplier’s stock worth $77,135,000 after acquiring an additional 16,315 shares during the period. Point72 Asset Management L.P. raised its position in Glaukos by 13.8% during the second quarter. Point72 Asset Management L.P. now owns 1,321,902 shares of the medical instruments supplier’s stock worth $60,041,000 after acquiring an additional 160,347 shares during the period. Assenagon Asset Management S.A. raised its position in Glaukos by 513.3% during the second quarter. Assenagon Asset Management S.A. now owns 900,108 shares of the medical instruments supplier’s stock worth $40,883,000 after acquiring an additional 753,348 shares during the period. Finally, Primecap Management Co. CA raised its position in Glaukos by 1.7% during the second quarter. Primecap Management Co. CA now owns 541,370 shares of the medical instruments supplier’s stock worth $24,589,000 after acquiring an additional 8,870 shares during the period. 92.17% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on GKOS shares. Needham & Company LLC dropped their target price on shares of Glaukos from $66.00 to $65.00 and set a “buy” rating for the company in a report on Thursday, November 3rd. Citigroup raised shares of Glaukos from a “neutral” rating to a “buy” rating and set a $57.00 price objective for the company in a report on Monday, December 12th. JPMorgan Chase & Co. raised shares of Glaukos from an “underweight” rating to a “neutral” rating and lowered their target price for the stock from $48.00 to $42.00 in a research note on Monday, December 19th. StockNews.com lowered shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Tuesday. Finally, Mizuho assumed coverage on shares of Glaukos in a research note on Thursday, December 22nd. They set a “neutral” rating and a $48.00 target price for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $56.67.
Glaukos Stock Down 2.0 %
Glaukos (NYSE:GKOS – Get Rating) last issued its earnings results on Wednesday, November 2nd. The medical instruments supplier reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.08. The firm had revenue of $71.27 million for the quarter, compared to analysts’ expectations of $67.88 million. Glaukos had a negative net margin of 31.45% and a negative return on equity of 16.16%. As a group, equities research analysts predict that Glaukos Co. will post -2.23 earnings per share for the current fiscal year.
Glaukos Company Profile
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B.
- Get a free copy of the StockNews.com research report on Glaukos (GKOS)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.